Abeona Therapeutics (NASDAQ:ABEO) Downgraded to Sell at StockNews.com

Abeona Therapeutics (NASDAQ:ABEO) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday.

Abeona Therapeutics Trading Down 7.0 %

Shares of ABEO opened at $3.17 on Tuesday. Abeona Therapeutics has a 12 month low of $2.83 and a 12 month high of $9.01. The firm’s 50 day moving average is $7.43 and its 200-day moving average is $5.65. The stock has a market capitalization of $86.70 million, a PE ratio of -1.23 and a beta of 1.49.

Abeona Therapeutics (NASDAQ:ABEO) last announced its earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.13). Equities research analysts predict that Abeona Therapeutics will post -1.83 earnings per share for the current fiscal year.

Institutional Trading of Abeona Therapeutics

Large investors have recently made changes to their positions in the company. Simplex Trading LLC boosted its position in shares of Abeona Therapeutics by 1,889.9% during the 3rd quarter. Simplex Trading LLC now owns 14,128 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 13,418 shares in the last quarter. Jump Financial LLC acquired a new stake in shares of Abeona Therapeutics during the 4th quarter worth approximately $199,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Abeona Therapeutics during the 3rd quarter worth approximately $648,000. Worth Venture Partners LLC boosted its position in shares of Abeona Therapeutics by 76.6% during the 3rd quarter. Worth Venture Partners LLC now owns 281,280 shares of the biopharmaceutical company’s stock worth $1,184,000 after acquiring an additional 121,969 shares in the last quarter. Finally, Barclays PLC boosted its position in shares of Abeona Therapeutics by 100.0% during the 3rd quarter. Barclays PLC now owns 371,276 shares of the biopharmaceutical company’s stock worth $1,564,000 after acquiring an additional 185,638 shares in the last quarter. Institutional investors and hedge funds own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.